DECLARATION OF INTERESTS STATEMENT

Editor name: James Gulley (Editor-in-Chief)

Journal: Journal for ImmunoTherapy of Cancer

I have read and understood the BMJ's policy on declaration of interests and declare the following:

Lecture Honoria: None
Paid Advisory Boards: None
Unpaid Advisory Boards: Gritstone, Ankyra, Marengo, EMD Serono, Definiens, Janssen, Loma Linda University, McCann, Medical University of S.C., Merck, Astra Zeneca, SapVax, AACR/SU2C, Visopharm, Jefferson Sydney Kimmel Cancer Center, Society for Immunotherapy of Cancer Patent: Combination PDL1 and TGF-beta blockade in patients with HPV+ malignancies Research funding to Inst: The National Cancer Institute has Cooperative Research and Development Agreements (CRADAs) with EMD Serono, Immunity Bio, and Therion Biologics. These CRADAs provide resources for co-development of experimental agents. Educational Grant to Inst: CRADA with EMD Serono for an Immunotherapy Fellowship Program.

Date: 6th March 2024